资源描述：
《2012_Citeline_Pharma_RD_Annual_Review》由会员上传分享，免费在线阅读，更多相关内容在学术论文-天天文库。
1、PharmaR&DAnnualReview2012IanLloyd,CitelineEditorialDirectorMayisthetimewhenCiteline’sAnnualReviewoftrendsinpharmaceuticalR&Distraditionallyconducted.Itisausefulopportunitytopauseandreflectonhowtheindustryiscontinuingtoevolve,andisalsothetimewhenwetakethe
2、annualsnapshotofourdatatoprovideanewtimepointforevaluatingtrendsfromourPharmaprojectsPipelinedrugintel-ligenceservice.Inthisarticle,weexaminethedatafor2012,lookathowithaschangedsince2011,andtrytoputtheinformationintosomesortofcontext.Someofthekeypointsco
3、veredinthisreportinclude:•SizeablegrowthintheoverallR&Dpipeline•GSKreplacesPfizerasthecompanywithmostdrugsindevelopment•Astandoutyearfornewactivesubstanceslaunches•IncreaseinR&Damongstart-upandnichecompanies•PromisinggrowthofdrugsincrucialPhaseIIItrials•
4、StrikingaccelerationinoncologyresearchExaminingtheoverallnumberofActivedrugsintheSowhatdoesthisapparentpipelinegrowthmean?Onepipelineisalwaysagoodplacetostart,asitgivesanthingwhichisalwaysdifficultistheteasingapartofrealoverallflavourofthedirectioninwhic
5、hthingsareworldchangesversustheeffectonthefiguresofheaded.Andthisyear,thereisacheeringincreaseinimprovededitorialpracticesanddetection.Clearly,weevidence.Afterthefiguresstagnatedfrom2010to2011,atCitelinearecontinuouslystrivingtoimproveourthe2012totalnumb
6、erofR&Ddrugsisupto10,452,aprocessestomakeourdataincreasinglycomprehensive,7.6%increasefromlastyear’sfigure.Leavingasidetheandthisyearhasbeennoexception.However,itseems2007-2008rise,whichissomethingofanaberrationhighlyunlikelythatthiswouldaccountforanincr
7、easeascausedbythebringingtogetherofdrugdatafromourlargeas739drugs.Ourbestguesswouldbethatbetteroriginaldatabasewiththatofthethennewly-acquireddatacollectionmightaccountfor2-3.5%ofthisincrease,Citelinedatabaseofclinicaltrials(Trialtrove),thiswhichwouldsti
8、llleaveasizeablegrowthintheoverallrepresentsthelargestincreaseinpercentagetermsreportedpipeline,notbadinaneraofausterity.Sooursince2003-2004’s9.0%.reviewof2012kicksoffonapositivenote,andwe’llFigure1:ToTalSizeoFThepipeline2
